President-elect Trump Makes More HHS Personnel Moves: Dr. Marty Makary Tapped to Lead FDA

November 25, 2024

Reading Time : 4 min

In recent days, President-elect Trump has made progress in announcing the names of various individuals he intends to nominate to serve in some of the most senior and influential leadership positions at the Department of Health and Human Services (HHS) and which also require Senate confirmation. The first of these announcements was that President-elect Trump intends to nominate RFK Jr. to serve as HHS Secretary. The HHS Secretary is responsible for overseeing all 13 of the Department’s Operating Divisions, including the FDA, in addition to the Department’s staff divisions. President-elect Trump also recently announced his intent to nominate physician and former Representative Dave Weldon (R-FL) to serve as the next Director of the Centers for Disease Control and Prevention and Dr. Janette Nesheiwat as the next Surgeon General.

President-elect Trump announcing his intent to nominate Dr. Makary to serve as the next Commissioner of Food and Drugs is the first step in the Senate confirmation process. Once the 119th Congress commences early next year, his nomination would be expected to be taken up by the Senate Health, Education, Labor and Pensions (HELP) Committee, including the HELP Committee holding a hearing on his nomination during which senators on both sides of the aisle who serve on that the Committee would likely delve into Dr. Makary’s previous health policy commentary. He will likely be asked a range of questions about how he would approach the role of Commissioner. Dr. Makary’s previous criticism of the FDA appears to be more nuanced than some of the other HHS nominees named by President-elect Trump thus far. His confirmation is subject to a 50-vote threshold, and with a Republican majority of 53 Senate seats, it is likely to be more of a question as to when, not if, Dr. Makary is confirmed to serve as the next Commissioner of Food and Drugs.

The Commissioner of Food and Drugs is one of the most anticipated political appointee nominations, given the breadth of the FDA’s mission to protect and promote public health. FDA is responsible for ensuring the safety, efficacy and security of human and veterinary drugs, biological products and medical devices. The agency is also charged with ensuring the safety of our nation’s food supply, cosmetics and products that emit radiation. In addition, FDA regulates the manufacturing, marketing and distribution of tobacco products. FDA ensures the security of the food supply and fosters development of medical products to respond to public health threats whether naturally occurring, like an emerging infectious disease, or deliberate.

The agency’s regulatory responsibilities are vast and impacts are not limited to patients and public health but also extend to the economy: FDA-regulated products account for 20 cents of every dollar spent by U.S. consumers. Even though FDA does not have a direct role in medical product pricing, how the agency’s regulatory frameworks are structured and implemented does impact the timing its takes for products to reach the market, whether they are new innovations for unmet public health needs or those like generic drugs, and medical devices cleared under 510(k) as substantially equivalent, which may expand choices for consumers and thereby foster competition.

Marty Makary, M.D., M.P.H., a board certified surgeon, is Chief of Islet Transplant Surgery at The Johns Hopkins University. He has written extensively on health care, including publishing two New York Times bestsellers, scientific peer-reviewed articles and commentary for national publications like the Washington Post, Wall Street Journal and New York Times, in addition to Fox News appearances. While Dr. Makary would be new to FDA, he is not new to Washington, D.C.’s policy scene, having served as an advisor to the health care think tank Paragon Health Institute. Dr. Makary would also bring experience having advised life sciences companies and served in leadership at the World Health Organization.

As Commissioner, Dr. Makary would assume the role of leading an agency comprised of more than 18,000 employees spanning the agency’s medical product centers, human foods program, and tobacco products center and implementing regulatory frameworks that rely upon billions in taxpayer dollars and industry collected user fees to sustain regulatory certainty for the premarket review of products overseen by FDA and related performance goals. As the commissioners who have come before him, Dr. Makary would have the opportunity to chart his priorities for the agency in assuming its helm. However, he is destined to face the Goldilocks dilemma inherent to leading the agency: no matter the time and approach the agency takes, there will likely be those that say the agency moved too fast, too slow, too far or not far enough. Indeed, FDA’s actions are consistently an area of intense focus by patients, consumers, the public health community, clinicians, industry stakeholders and Congress. Yet, the scrutiny Dr. Makary may have to navigate as Commissioner may set a new high watermark as he would be entrusted with carrying out the agency’s public health mission against the backdrop of an incoming administration expected to prioritize government-wide deregulatory action and the first administration to establish its regulatory agenda post the Loper Bright decision, and alongside administration colleagues who have criticized the agency and may have varying expectations as to what they would view as success for it over the next four years.

Share This Insight

Previous Entries

Eye on FDA

April 16, 2025

On April 10, 2025, the Food and Drug Administration (FDA) announced its plan to replace animal testing in the development of monoclonal antibody therapies and other drugs in one of the first announcements by the agency since Commissioner Makary was confirmed to lead it. In its announcement, FDA highlighted that this more modern approach is designed to improve drug safety and accelerate the evaluation process, while also reducing animal experimentation, lowering research and development costs, and lowering drug prices.

...

Read More

Eye on FDA

April 2, 2025

On March 31, 2025, Judge Sean D. Jordan of the U.S. District Court for the Eastern District of Texas issued an opinion and judgment in American Clinical Laboratory Association v. FDA. Judge Jordan’s decision vacates and sets aside the Food & Drug Administration’s (FDA) final rule, Medical Devices; Laboratory Developed Tests (the LDT Rule).1 The LDT Rule would have required laboratories offering LDTs to meet medical device requirements. The preamble to the LDT Rule provided a multi-stage phase out of FDA’s enforcement discretion policy, under which the first set of regulatory requirements would have been actively enforced beginning May 6. While many labs are breathing a sigh of relief after the publication of this order, questions remain as to how the agency will proceed and the broader implications for regulation of lab tests and in vitro diagnostics generally.

...

Read More

Eye on FDA

March 24, 2025

In the past week, the U.S. Food and Drug Administration (FDA), in collaboration with the Department of Health and Human Services (HHS) announced three new initiatives related to food safety and food supply chain transparency. Outlined below, these new initiatives align with HHS Secretary Robert F. Kennedy Jr.’s recent announcements to focus on bolstering food safety, including the recent directive to the FDA to explore the revision of the longstanding Generally Recognized as Safe (GRAS) rule.

...

Read More

Eye on FDA

March 12, 2025

The Food and Drug Administration (FDA) has updated its website to provide new information on data integrity concerns relating to medical devices.

...

Read More

Eye on FDA

March 12, 2025

United States Department of Health and Human Services (HHS) Secretary Kennedy recently directed the U.S. Food and Drug Administration (FDA) to consider rulemaking to revise its longstanding regulations and guidance governing the oversight of food ingredients to eliminate the ability of individuals and companies to self-affirm that their ingredients are Generally Recognized as Safe (GRAS). This would mark a massive shift in how new food ingredients are introduced to the market.

...

Read More

Eye on FDA

January 21, 2025

In the final stretch of the Biden administration, the Food and Drug Administration (FDA) laid the groundwork for continued engagement with the public on two challenging areas of product development, each of which is of high interest to patients, clinical communities, industry stakeholders and policy-makers in Congress.

...

Read More

Eye on FDA

January 17, 2025

On January 6, 2025, the FDA released final guidance for industry entitled “Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers.” The guidance outlines FDA’s enforcement policy concerning certain firm-initiated communications of scientific information on unapproved uses (SIUU) of the firm’s approved or cleared medical products to health care providers involved in prescribing or administering those products to individual patients. It finalizes the October 2023 draft guidance, which itself revised draft guidance from 2014 and 2009. The latest guidance is not for current implementation and is pending the Office of Management and Budget’s (OMB) approval of the guidance’s information collection provisions.

...

Read More

Eye on FDA

January 16, 2025

On January 15, 2025, FDA announced an order revoking the listings providing for the use of the color additive FD&C Red No. 3 in both foods (including dietary supplements) and ingested drugs. The order is in response to a 2022 petition filed by the Center for Science in the Public Interest, among other food safety and health advocates, which asserted that the additive induces cancer in male rats and urged the agency to revoke authorization. 

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.